Are Female Patients More Overlooked in the Diagnosis of Fabry Disease?

References (5)

1. Barman HA, İkitimur B, Kılıçkıran Avcı B, Durmaz E, Atıcı A, Aslan S, et al. The Prevalence of Fabry disease Among Turkish Patients with Non-Obstructive Hypertrophic Cardiomyopathy: Insights from a Screening Study. Balkan Med J 2019;36:354-8
2. Hsu TR, Niu DM. Fabry disease: Review and experience during newborn screening. Trends Cardiovasc Med 2018;28:274-81
3. Yousef Z, Elliott PM, Cecchi F, Escoubet B, Linhart A, Monserratet L, et al. Left ventricular hyper-trophy in Fabry disease: a practical approach to diagnosis. Eur Heart J 2013;34:802-8
4. Hagège A, Réant P, Habib G, Damy T, Barone-Rochette G, Soulat G, et al. Fabry disease in cardiology practice: Literature review and expert point of view. Arch Cardiovasc Dis 2019;112:278-87
5. Biegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 2015;10:36